Skip to main content
SpringerLink
Log in

Unproven Hypotheses on the Cause of Alzheimer’s

  • Chapter
  • First Online:
Alzheimer’s Turning Point

  • 1102 Accesses

Abstract

The best way to tell the story of the Abeta hypothesis is to start with a concept that logically should have clearly explained the cause of Alzheimer’s disease 20 years ago, but did not. Before plunging into the many crevices that envelop the Abeta hypothesis, it is noteworthy to point out that when a widely held medical belief is shown to be wrong, proper treatment and management of patients associated with that belief will be less than desirable or conspicuously absent. Scientific proof in biology is generally difficult to demonstrate.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kuhn TS. The structure of scientific revolutions. 3rd ed. Chicago, Illinois: The University of Chicago Press; 1996. p. 24.

    Google Scholar 

  2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297:353–6.

    Article  CAS  PubMed  Google Scholar 

  3. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, Morrison JH, Gold G, Hof PR. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology. 2003;60(9):1495–500.

    Article  CAS  PubMed  Google Scholar 

  4. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58:376–88.

    Article  CAS  PubMed  Google Scholar 

  5. Braak H, Braak E. Frequency of stages of Alzheimerrelated lesions in different age categories. Neurobiol Aging. 1997;4:351–7.

    Article  Google Scholar 

  6. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087–95.

    Article  CAS  PubMed  Google Scholar 

  7. DeCarli C. Post-mortem regional neurofibrillary tangle densities, but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer disease patients. Neurodegeneration. 1992;1:11–20.

    Google Scholar 

  8. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT. PPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol. 1997;56:965–73.

    Article  CAS  PubMed  Google Scholar 

  9. Sassin I, Schultz C, Thal DR, Rüb U, Arai K, Braak E, Braak H. Evolution of Alzheimer’s disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol. 2000;100(3):259–69.

    Article  CAS  PubMed  Google Scholar 

  10. Liberski PP, Sikorska B, Hauw JJ, Kopp N. Ultrastructural characteristics (or evaluation) of Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies or prion diseases. Ultrastruct Pathol. 2010;34:351–61.

    Article  PubMed  Google Scholar 

  11. Larson ME, Lesne SE. Soluble Abeta oligomer production and toxicity. J Neurochem. 2012;120(Suppl 1):125–39.

    Article  CAS  PubMed  Google Scholar 

  12. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012;15(3):349–57.

    Article  CAS  PubMed  Google Scholar 

  13. Robakis NK. Are Abeta and its derivatives causative agents or innocent bystanders in AD? Neurodeg Dis. 2010;7(1–3):32–7.

    Article  CAS  Google Scholar 

  14. de la Torre JC. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer’s disease. N Engl J Med. 2014;370(15):1459–60.

    Google Scholar 

  15. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216–23.

    Article  CAS  PubMed  Google Scholar 

  16. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:311–21.

    Article  CAS  PubMed  Google Scholar 

  18. Kambhampaty A, Smith-Parker J. Eli Lilly’s solanezumab faces grim prospects of attaining conditional FDA approval in mild Alzheimer’s. Financial Times, 4 Sept 2012.

    Google Scholar 

  19. Ferrer I, Boada Rovira M, Sánchez Guerra ML, Rey MJ, Costa-Jussá F, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol. 2004;14:11–20.

    Article  CAS  PubMed  Google Scholar 

  20. Mondragón-Rodríguez S, Basurto-Islas G, Lee HG, Perry G, Zhu X, Castellani RJ. Causes versus effects: the increasing complexities of Alzheimer’s disease pathogenesis. Expert Rev Neurother. 2010;10:683–91.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631–9.

    Article  CAS  PubMed  Google Scholar 

  22. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357:169–75.

    Google Scholar 

  23. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275–83.

    Google Scholar 

  24. Keefe PR. The empire edge. The New Yorker, 13 Oct 2015. p. 76–89.

    Google Scholar 

  25. Shamoo AE, Resnick DB. Responsible conduct of research. 3rd ed. New York: Oxford University Press;2015. p. 106.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas at Austin, Austin, TX, USA

    Jack C. de la Torre

Authors
  1. Jack C. de la Torre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jack C. de la Torre .

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

de la Torre, J.C. (2016). Unproven Hypotheses on the Cause of Alzheimer’s. In: Alzheimer’s Turning Point. Springer, Cham. https://doi.org/10.1007/978-3-319-34057-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34057-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34056-2

  • Online ISBN: 978-3-319-34057-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation